---
title: "CSPC Innovation Pharma, CSPC Pharmaceutical Group unit, forecasts H1 net profit at 1.18 billion-1.36 billion yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293909868.md"
description: "CSPC Innovation Pharma, a subsidiary of CSPC Pharmaceutical Group, forecasts H1 2026 net profit attributable to shareholders between CNY 1.18 billion and CNY 1.36 billion, marking a significant turnaround from a CNY 2.75 million loss in the same period last year. The positive outlook is driven by revenue recognition from a $420 million upfront payment from AstraZeneca received on May 29, alongside advanced commercial rollouts for key drugs including Enlonstobart Injection, Omalizumab, and Ustekinumab."
datetime: "2026-07-27T09:34:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293909868.md)
  - [en](https://longbridge.com/en/news/293909868.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293909868.md)
generator: "portal-rs"
---

# CSPC Innovation Pharma, CSPC Pharmaceutical Group unit, forecasts H1 net profit at 1.18 billion-1.36 billion yuan

-   CSPC Innovation Pharmaceutical, a subsidiary of CSPC Pharmaceutical Group, guided for H1 2026 net profit attributable to shareholders of CNY 1.18-1.36 billion. \* That compares with a net loss of CNY 2.75 million a year earlier. \* Net profit after deducting non-recurring items seen at CNY 1.15-1.33 billion versus a loss of CNY 41.14 million. \* Turnaround driven by revenue recognition from a US$420 million AstraZeneca upfront payment received on May 29. \* Commercial rollout advanced for Enlonstobart Injection, Omalizumab for Injection, Ustekinumab Injection. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260727-12257425), on July 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)
- [300765.CN](https://longbridge.com/en/quote/300765.CN.md)
- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [CSPC Pharma wins China NMPA clearance to start Phase 1 trial of SYH2092 obesity drug](https://longbridge.com/en/news/297512143.md)
- [AstraZeneca Reports Positive Results Of SANOVO Phase III Trial In China](https://longbridge.com/en/news/297606938.md)
- [CSPC Pharma says FDA grants Fast Track status to SYS6090 for MSS/pMMR metastatic colorectal cancer](https://longbridge.com/en/news/297024431.md)
- [CSPC says FDA clears RSV vaccine candidate SYS 6057 for US clinical trial](https://longbridge.com/en/news/296903628.md)
- [Key facts: LSE:AZN Zegfrovy buy; SANOVO PFS; Wan Ling Martello named](https://longbridge.com/en/news/297611733.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**